MARKET

AMGN

AMGN

Amgen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

258.24
+3.12
+1.22%
After Hours: 258.70 +0.46 +0.18% 19:47 07/02 EDT
OPEN
252.87
PREV CLOSE
255.12
HIGH
261.46
LOW
252.87
VOLUME
3.34M
TURNOVER
--
52 WEEK HIGH
256.23
52 WEEK LOW
173.12
MARKET CAP
151.91B
P/E (TTM)
20.23
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 29 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AMGN stock price target is 255.25 with a high estimate of 291.00 and a low estimate of 185.00.

EPS

AMGN News

More
Top Research Reports for Netflix, Exxon Mobil & Amgen
Zacks · 2d ago
The Top-Ranked Dividend Growth Stocks In The Health Care Sector
Seeking Alpha - Article · 2d ago
Amgen Gets Favorable Appeals Court Ruling for Enbrel Patent
Zacks · 2d ago
Amgen (AMGN) Looks Good: Stock Adds 8.2% in Session
Zacks · 2d ago
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 2d ago
US Indexes Close Mostly Higher to Start July
Nasdaq gains 0.95% Continue reading...
GuruFocus.com · 3d ago
Amgen's Win, Netflix's Hire Send Nasdaq Higher
Motley Fool · 3d ago
Why Amgen Shares Jumped Today
Motley Fool · 3d ago

Industry

Pharmaceuticals
+0.58%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About AMGN

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
More

Webull offers kinds of Amgen, Inc. stock information, including NASDAQ:AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.